| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
|
Feldman, Eric J.
|
|
2011
|
24 |
4 |
p. 523-526
4 p.
|
article
|
| 2 |
Editorial Board / Aims & Scope
|
|
|
2011
|
24 |
4 |
p. iii-
1 p.
|
article
|
| 3 |
Evaluation of prognostic factors in AML
|
Rowe, Jacob M.
|
|
2011
|
24 |
4 |
p. 485-488
4 p.
|
article
|
| 4 |
Flow cytometry in the post fluorescence era
|
Nolan, Garry P.
|
|
2011
|
24 |
4 |
p. 505-508
4 p.
|
article
|
| 5 |
Genomic profiling of B-progenitor acute lymphoblastic leukemia
|
Mullighan, Charles G.
|
|
2011
|
24 |
4 |
p. 489-503
15 p.
|
article
|
| 6 |
Index
|
|
|
2011
|
24 |
4 |
p. I-
1 p.
|
article
|
| 7 |
Is a nadir bone marrow required and, if so, what to do with residual disease?
|
Luger, Selina M.
|
|
2011
|
24 |
4 |
p. 527-532
6 p.
|
article
|
| 8 |
Research and discovery of the first human cancer virus, HTLV-1
|
Gallo, Robert C.
|
|
2011
|
24 |
4 |
p. 559-565
7 p.
|
article
|
| 9 |
Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
|
Stone, Richard M.
|
|
2011
|
24 |
4 |
p. 509-514
6 p.
|
article
|
| 10 |
Targeted immunotherapy for acute myeloid leukemia
|
Vasu, Sumithira
|
|
2011
|
24 |
4 |
p. 533-540
8 p.
|
article
|
| 11 |
The role of hematopoietic cell transplantation as therapy for myelodysplasia
|
Appelbaum, Frederick R.
|
|
2011
|
24 |
4 |
p. 541-547
7 p.
|
article
|
| 12 |
Transplants for leukemia in relapse: When is the best time?
|
Weisdorf, Daniel
|
|
2011
|
24 |
4 |
p. 549-552
4 p.
|
article
|
| 13 |
What is the optimal induction strategy for older patients?
|
Estey, Elihu
|
|
2011
|
24 |
4 |
p. 515-522
8 p.
|
article
|
| 14 |
What is the potential for thrombopoietic agents in acute leukemia?
|
Kuter, David J.
|
|
2011
|
24 |
4 |
p. 553-558
6 p.
|
article
|
Journal description